CDK4 and mantle cell lymphoma: However, clinical trials of CDK inhibitors in MCL, such as Palbociclib [20] (CDK4/6 inhibitor), showed an overall response rate (ORR) of 18% and complete response (CR) of 8% in previously treated MCL [20].